Captor Therapeutics Sa · GPW:CTX
Captor Therapeutics Sa — H1 2023 Earnings Presentation
26 slides from Captor Therapeutics Sa's earnings presentation, Sep 7, 2023
Slide 1: H1 2023 update Corporate Presentation
H1 2023 update Corporate Presentation September 2023
Slide 2: Legal notice
Legal notice This document and the information contained herein (unless otherwise indicated) have been prepared by Captor Therapeutics S.A. (the “Issuer”) solely for informational purposes. For this notice, the presentation that follows shall mean and include the slides that follow, the oral present
Slide 3: Corporate Summary
Poe Captor ° Therapeutics CORPORATE SUMMARY
Slide 4: Captor Therapeutics – key take-aways in H1 2023
Captor Therapeutics – key take-aways in H1 2023 Corporate ✓ Announcement of the next steps in the Strategy - increase of authorised share capital PLN 38,2 M incurred for R&D ✓ Strengthening of the scientific and business team Cash flow supported by non-dilutive grant ✓ Cooperation with international
Slide 5: Roadmap to our strategic objectives
Roadmap to our strategic objectives Fully-owned portfolio of owned clinical and preclinical assets, while sharing development or commercial risks with partners at the optimum time for each asset. 4 active pipeline projects* Optigrade™ Platform Clinical trials in patients of Further preclinical work
Slide 6: Significant strengthening of the team
Significant strengthening of the team Donald Coppen Andrew Saunders Tomas Drmota Business Development Director Chief Medical Officer VP Early Discovery • PhD Southampton University • MD Trinity College Dublin • Ph.D. Charles Univ. Prague • MBA Cranfield University • Over 20 years of experience in •
Slide 7: International financial advisors
International financial advisors • Exclusive strategic financial advisor • Specialist healthcare business development broker focused • Identification and evaluation of potential strategic on Greater China opportunities: • Objective is to establish potential partnerships in Greater ➢ licensing or par
Slide 8: Ono Pharmaceutical - a strong partner for Captor
Ono Pharmaceutical - a strong partner for Captor Worldwide drug discovery collaboration with Ono Pharmaceutical to develop novel small molecule degrader drugs against a currently undrugged target of interest in neurodegenerative diseases. Other ONO partnerships Payment of remuneration to the Company
Slide 9: Development of Projects
Captor Poe Therapeutics” DEVELOPMENT OF PROJECTS
Slide 10: Fully owned pipeline
Fully owned pipeline # Target Indications Modality Discovery Preclinical* IND Filing Phase IA / IB FIH** GSPT1, CT-01 Hepatocellular carcinoma, NEK7, MG SALL4 Lung cancer, NET tumours Autoimmunity, CNS, CT-02 NEK7 MG Metabolism, Oncology CT-03 MCL-1 Liquid & solid tumours BID CT-05 PKCӨ Autoimmunity
Slide 11: CT-01: Multi-target GSPT1, NEK7 & SALL4 degrader
CT-01: Multi-target GSPT1, NEK7 & SALL4 degrader Lung cancer 400k patients GSPT1 degradation leads to an Integrated Stress Response and induction of apoptosis in HCC cells SALL4 is expressed in fetal liver, silenced in adults, but often re-expressed in HCC and correlates with poor prognosis NEK7 deg
Slide 12: Recent achievements
Recent achievements • Completion of GLP-tox in life phase with no gross findings • Awaiting histopathology and full report • Demonstrated combination with everolimus potentiates degradation of target proteins • Status: • Production of a GMP-batch and drug product for clinical studies ongoing • IB in
Slide 13: CT-02: Vast market potential for inflammasome modulators
CT-02: Vast market potential for inflammasome modulators Neuroinflammation Allergy Asthma (AD, PD, MS, ALS) Myocardial infarction Fibrotic diseases Diabetic cardiomyopathy Lupus Inflammatory nephritis Bowel Disease Gout Psoriasis Rheumatoid Arthritis 13 Business Use Only | Do not use without written
Slide 14: Lead compounds show excellent selectivity profile / safety profile
Lead compounds show excellent selectivity profile / safety profile Lead 1 Lead 2 Lead-BBB All the lead compounds demonstrate high safety profile in CEREP panel 14 Business Use Only | Do not use without written consent of Captor Therapeutics Inc. © 2023
Slide 15: CT-03: MCL-1 – a critical pathway of cancer resistance
CT-03: MCL-1 – a critical pathway of cancer resistance Lung cancer 400k patients MCL-1 is one of the most amplified proteins in cancer A critical resistance mechanism in haematological and solid tumours Degradation of inhibition of MCL-1 protein directly attenuates tumours Breast Cancer in vivo as m
Slide 16: Milestones
Milestones • Two MCL-1 bifunctional degraders have been developed with high potency (DC50) of <1 nM and 100 nM • Both compounds potently inhibit tumor growth in vivo • Both compounds do not affect NHP troponin-I (a marker of heart muscle damage) levels at doses higher than the effective doses • ~1 k
Slide 17: CT-05: PKCӨ an inadequately drugged high value target
CT-05: PKCӨ an inadequately drugged high value target TCR Multiple sclerosis Allergy Asthma CD3 CD28 T-cell membrane Cytoplasm Myocarditis Breast cancer PKCӨ IL-2 Kidney injury IL-17 Gastrointestinal cancer Nucleus Inflammatory Bowel Psoriasis Disease 17 Business Use Only | Do not use without writte
Slide 18: Best-in-class selectivity
Best-in-class selectivity KinomeScan results Inhibitor shows significant effects on non-immune cells TREEspot™ Interaction Map Degrader has no effect in non-immune cells panel of ca. 450 kinases 0.1 µM 0.5 µM BigPharma compound ABS-911 Inadequate Selectivity Lead compound High Selectivity Compound I
Slide 19: Optigrade discovery platform – importance of structure & chemistry
OptigradeTM discovery platform – importance of structure & chemistry OptigradeTM – addressing Molecular Glues, Bifunctional Degraders and novel Ubiquitin E3 Ligases Leading chemistry expertise in creating “activated” degraders to increase intracellular potency 19 Business Use Only | Do not use witho
Slide 20: Optigrade discovery platform
OptigradeTM discovery platform Molecular New E3 Glue CT-09 Ligases • First-in-class degrader of an Intrinsically Disordered Protein (IDP) • Demonstrated first degradation of a target protein using the novel ligase KLHDC2 • High commercial potential in CRC, hematological cancers and immuno-oncology •
Slide 21: Financials and Plans for the Future
FINANCIALS AND PLANS FOR THE FUTURE 21
Slide 22: Strong balance sheet and cash position
Strong balance sheet and cash position Cash position Consolidated statement of financial position (PLN, M) Available funding secured (PLN M; as of June 30, 2023): 101,3 96,3 Total : - PLN 137,4 M PLN 58,7 68,6 cash, short-term bonds 58,7 55,5 137,4 78,7 PLN 78,7 available grants (NCBR; ABM) 20,5 11,
Slide 23: Next steps
Next steps 2023 • CT-01: Submit Clinical Trial Authorisation application • CT-02 and CT-05: In vivo proof of concept in autoimmunity • In cell degradation of target with novel E3 ligase-based degrader 2024 • CT-03: Submit Clinical Trial Authorisation application • CT-01: Clinical readouts: safety, p
Slide 24: Q&A Session
Poe Captor ° Therapeutics Q&A SESSION
Slide 25: Captor Therapeutics S.A ul. Duńska 11 54-427 Wrocław, Poland
Captor Therapeutics S.A ul. Duńska 11 54-427 Wrocław, Poland Captor Therapeutics GmbH Hegenheimermattweg 167A 4123 Allschwil, Switzerland Contact: relacje.inwestorskie@captortherapeutics.com
Slide 26: Projects co-financed by the European Regional Development Fund
Projects co-financed by the European Regional Development Fund: Discovery and development of a new clinical drug candidate for the eradication of cancer stem cell in the treatment of hepatocellular carcinoma, through degradation of oncofetal transcription factor (POIR.01.01.01-00-0740/19-00) Discove